New deputy director of Mayo Clinic Cancer Center in Arizona
Volume 6, Issue 4, 2017
Dr. Sekulic, whose research focuses on cutaneous oncology, oversees strategic planning and management.
Aleksandar Sekulic, M.D., Ph.D.
Aleksandar Sekulic, M.D., Ph.D., has been named deputy director of the Mayo Clinic Cancer Center in Arizona.
In this new role, Dr. Sekulic oversees National Cancer Institute-designated comprehensive cancer center activities at Mayo Clinic's campus in Arizona. He is responsible for Mayo Clinic Cancer Center strategic planning and management in Arizona and coordinates and integrates those activities with Mayo Clinic Cancer Center leadership at Mayo Clinic's campuses in Florida and Minnesota.
Dr. Sekulic is an associate professor in the Department of Dermatology in Arizona. His research spans several clinical and translational disciplines in the area of cutaneous oncology, and he has two National Institutes of Health Research Program Project (R01) grants. Dr. Sekulic is also a principal on the Stand Up to Cancer Melanoma Dream Team project called Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer.
Dr. Sekulic was principal investigator on the ERIVANCE trial, which led the Food and Drug Administration to approve vismodegib, the first hedgehog pathway inhibitor for the treatment of basal cell carcinoma. Results of the ERIVANCE trial were published June 7, 2012, in the New England Journal of Medicine.
In addition to his new role with the Cancer Center, Dr. Sekulic is associate director of the Center for Individualized Medicine and vice chair of the Department of Dermatology at Mayo Clinic. He also has roles on national cancer advisory panels, including the American Academy of Dermatology and the National Comprehensive Cancer Network.